Volociximab  (Synonyms: M200; Eos 200-4)

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs)^[1][2].

Volociximab (20, 40, 80, 160, 320 nM) specifically targets integrin α5β1 (K_d=0.367 nM), but not integrin α5α5 or β1β1^[1].
Volociximab (0.01-100 nM; 4 d) inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVEC) (IC₅₀=0.2-0.5 nM) and (10 μg/mL; 16 h) induces apoptosis in schizogenic but not senescent Huvecs^[1].
Volociximab (0.067-67 nM; 6 d) inhibits 0.1 μg/mL VEGF and/or bFGF induced HUVEC angiogenesis in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Volociximab (300 μg/eye; intravitreal injection; once weekly for 4 weeks) has well tolerance and inhibits angiogenesis in laser induced choroidal neovascularization (CNV) of cynomolgus monkey model^[1].
Volociximab (10 mg/kg; i.v.; twice weekly for 3 weeks) suppresses tumor progress in rabbits VX2 model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145.5 kDa (Average)

558480-40-3

Liquid

Colorless to light yellow

[Volociximab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bhaskar V, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26(1):7-12.  [Content Brief]

  [2]. Ramakrishnan V, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.  [Content Brief]